CanSino Biologics (HKSE:06185) EV-to-EBIT : -3.56 (As of May. 14, 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CanSino Biologics's Enterprise Value is HK$7,318.7 Mil. CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-2,055.4 Mil. Therefore, CanSino Biologics's EV-to-EBIT for today is -3.56.

The historical rank and industry rank for CanSino Biologics's EV-to-EBIT or its related term are showing as below:

HKSE:06185' s EV-to-EBIT Range Over the Past 10 Years
Min: -44.72 Med: -1.97 Max: -0.93
Current: -3.47

During the past 8 years, the highest EV-to-EBIT of CanSino Biologics was -0.93. The lowest was -44.72. And the median was -1.97.

HKSE:06185's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.92 vs HKSE:06185: -3.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CanSino Biologics's Enterprise Value for the quarter that ended in Mar. 2024 was HK$1,878.6 Mil. CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-2,055.4 Mil. CanSino Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -109.41%.

CanSino Biologics EV-to-EBIT Historical Data

The historical data trend for CanSino Biologics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics EV-to-EBIT Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-71.49

-80.20

15.61

-10.54

-2.05

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial													-7.09	-1.69	-1.66	-2.05	-0.91

Competitive Comparison of CanSino Biologics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's EV-to-EBIT falls into.

CanSino Biologics EV-to-EBIT Calculation

CanSino Biologics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	7318.699	/	-2055.369
	=	-3.56

CanSino Biologics's current Enterprise Value is HK$7,318.7 Mil.
CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2,055.4 Mil.

CanSino Biologics (HKSE:06185) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CanSino Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-2055.369	/	1878.605
	=	-109.41 %

CanSino Biologics's Enterprise Value for the quarter that ended in Mar. 2024 was HK$1,878.6 Mil.
CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2,055.4 Mil.

CanSino Biologics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » EV-to-EBIT

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (HKSE:06185) Headlines

No Headlines